{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:26:12Z","timestamp":1790961972199,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["961905"],"award-info":[{"award-number":["961905"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jconrel.2023.01.034","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T20:23:29Z","timestamp":1674159809000},"page":"453-464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma"],"prefix":"10.1016","volume":"354","author":[{"given":"Vajiheh","family":"Jahani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Yazdani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Badiee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud Reza","family":"Jaafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Arabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.jconrel.2023.01.034_bb0005","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1200\/JCO.2007.14.6423","article-title":"Next generation of immunotherapy for melanoma","volume":"26","author":"Kirkwood","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0065-2776(08)60675-6","article-title":"Immune response against tumors","volume":"57","author":"Roth","year":"1994","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.biomaterials.2016.10.047","article-title":"Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine","volume":"113","author":"Shi","year":"2017","journal-title":"Biomater."},{"issue":"10","key":"10.1016\/j.jconrel.2023.01.034_bb0020","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.87059","article-title":"PD-1 blockade enhances the vaccination-induced immune response in glioma","volume":"1","author":"Antonios","year":"2016","journal-title":"JCI Insight."},{"issue":"7","key":"10.1016\/j.jconrel.2023.01.034_bb0025","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.3390\/cancers12071826","article-title":"Advances in anti-Cancer immunotherapy: Car-T cell, checkpoint inhibitors, dendritic cell vaccines, and oncolytic viruses, and emerging cellular and molecular targets","volume":"12","author":"Alard","year":"2020","journal-title":"Cancers."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0030","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jconrel.2022.01.003","article-title":"Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy","volume":"342","author":"Ni","year":"2022","journal-title":"J. Control. Rel. Offic. J. Controlled Rel. Soc."},{"issue":"6","key":"10.1016\/j.jconrel.2023.01.034_bb0035","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.drudis.2021.02.017","article-title":"A paradigm shift in cancer nanomedicine: from traditional tumor targeting to leveraging the immune system","volume":"26","author":"Sofias","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2023.01.034_bb0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jconrel.2022.03.020","article-title":"A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and PolyIC RNA","volume":"345","author":"Carson","year":"2022","journal-title":"J. Control. Rel. Offic. J. Controlled Rel. Soc."},{"issue":"28","key":"10.1016\/j.jconrel.2023.01.034_bb0045","doi-asserted-by":"crossref","first-page":"12133","DOI":"10.1021\/jacs.0c01928","article-title":"Potent and prolonged innate immune activation by enzyme-responsive Imidazoquinoline TLR7\/8 agonist prodrug vesicles","volume":"142","author":"Wang","year":"2020","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0050","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jconrel.2019.04.019","article-title":"MPL nano-liposomal vaccine containing P5 HER2\/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer","volume":"303","author":"Zamani","year":"2019","journal-title":"J. Control. Rel. Offic. J. Controlled Rel. Soc."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.034_bb0055","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0060","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2021.07.026","article-title":"Vaccine nanodiscs plus polyICLC elicit robust CD8+ T cell responses in mice and non-human primates","volume":"337","author":"Najafabadi","year":"2021","journal-title":"J. Control. Rel. Offic. J. Controlled Rel. Soc."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1421","article-title":"Delivery of therapeutics with nanoparticles: what\u2019s new in cancer immunotherapy?","volume":"9","author":"Fontana","year":"2017","journal-title":"Wiley Interdisciplinary Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2019.05.030","article-title":"Liposome and immune system interplay: challenges and potentials","volume":"305","author":"Zahednezhad","year":"2019","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.034_bb0075","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2174\/1567201813666160712164149","article-title":"Stimulation of tumor-specific immunity by p5 HER-2\/neu generated peptide encapsulated in Nano-liposomes with high phase transition temperature phospholipids","volume":"14","author":"Yazdani","year":"2017","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0080","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jconrel.2022.02.009","article-title":"Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis","volume":"343","author":"Rahiman","year":"2022","journal-title":"J. Control. Rel. Offic. J. Controlled Rel. Soc."},{"issue":"25","key":"10.1016\/j.jconrel.2023.01.034_bb0085","doi-asserted-by":"crossref","first-page":"28047","DOI":"10.1021\/acsami.0c08112","article-title":"Cationic liposome\/DNA complexes mediate antitumor immunotherapy by promoting immunogenic tumor cell death and dendritic cell activation","volume":"12","author":"Cong","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"5","key":"10.1016\/j.jconrel.2023.01.034_bb0090","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2217\/imt-2019-0173","article-title":"Ex vivo-generated dendritic cell-based vaccines in melanoma: the role of nanoparticulate delivery systems","volume":"12","author":"Yazdani","year":"2020","journal-title":"Immunotherapy."},{"issue":"15","key":"10.1016\/j.jconrel.2023.01.034_bb0095","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.addr.2012.05.009","article-title":"Cationic lipids activate intracellular signaling pathways","volume":"64","author":"Lonez","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.034_bb0100","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1021\/mp200350n","article-title":"Trp2 peptide vaccine Adjuvanted with (R)-DOTAP inhibits tumor growth in an advanced melanoma model","volume":"9","author":"Vasievich","year":"2012","journal-title":"Mol. Pharm."},{"issue":"15","key":"10.1016\/j.jconrel.2023.01.034_bb0105","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.2174\/092986711795656063","article-title":"The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer","volume":"18","author":"Cesario","year":"2011","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.034_bb0110","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2008.01.013","article-title":"Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma","volume":"54","author":"Dovedi","year":"2008","journal-title":"Eur. Urol."},{"issue":"15","key":"10.1016\/j.jconrel.2023.01.034_bb0115","doi-asserted-by":"crossref","first-page":"11397","DOI":"10.1074\/jbc.275.15.11397","article-title":"The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2","volume":"275","author":"Hsu","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1194\/jlr.M800122-JLR200","article-title":"The selective COX-2 inhibitor celecoxib modulates sphingolipid synthesis","volume":"50","author":"Schiffmann","year":"2009","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.034_bb0125","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0014-5793(02)03535-4","article-title":"Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells","volume":"531","author":"Yamazaki","year":"2002","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.jconrel.2023.01.034_bb0130","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/0008-5472.CAN-06-3780","article-title":"Celecoxib toxicity is cell cycle phase specific","volume":"67","author":"Bock","year":"2007","journal-title":"Cancer Res."},{"issue":"14","key":"10.1016\/j.jconrel.2023.01.034_bb0135","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1096\/fj.01-0299fje","article-title":"COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib","volume":"15","author":"Grosch","year":"2001","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2407-6-9","article-title":"The selective Cox-2 inhibitor celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in mice","volume":"6","author":"Klenke","year":"2006","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0145","first-page":"42","article-title":"Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer","volume":"30","author":"Wang","year":"2008","journal-title":"Exp. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0150","doi-asserted-by":"crossref","first-page":"20","DOI":"10.20892\/j.issn.2095-3941.2019.0339","article-title":"COX-2 as a potential biomarker and therapeutic target in melanoma","volume":"17","author":"Tudor","year":"2020","journal-title":"Cancer Biol. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.034_bb0155","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jcmgh.2021.06.021","article-title":"IDO in colorectal tumorigenesis: involvement of immune tolerance and significance in prevention and therapy","volume":"12","author":"Tang","year":"2021","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.jconrel.2023.01.034_bb0160","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1158\/2326-6066.CIR-16-0400","article-title":"Constitutive IDO1 expression in human tumors is driven by Cyclooxygenase-2 and mediates intrinsic immune resistance","volume":"5","author":"Hennequart","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.034_bb0165","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.4049\/jimmunol.177.4.2391","article-title":"Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO","volume":"177","author":"Basu","year":"2006","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0170","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/CJI.0b013e31818ac2f7","article-title":"The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells","volume":"32","author":"Lee","year":"2009","journal-title":"J. Immunother."},{"issue":"9","key":"10.1016\/j.jconrel.2023.01.034_bb0175","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/ijc.21616","article-title":"Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer","volume":"118","author":"Hahn","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.034_bb0180","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","article-title":"Celecoxib pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet. Genomics"},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0185","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12645-011-0017-5","article-title":"Effect of liposomal celecoxib on proliferation of colon cancer cell and inhibition of DMBA-induced tumor in rat model","volume":"2","author":"Perumal","year":"2011","journal-title":"Cancer Nanotechnol."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.034_bb0190","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00003088-200038030-00003","article-title":"Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor","volume":"38","author":"Davies","year":"2000","journal-title":"Clin. Pharmacokinet."},{"issue":"1\u20132","key":"10.1016\/j.jconrel.2023.01.034_bb0195","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ijpharm.2018.01.039","article-title":"Stable and sustained release liposomal formulations of celecoxib: in vitro and in vivo anti-tumor evaluation","volume":"540","author":"Matbou Riahi","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0200","doi-asserted-by":"crossref","first-page":"14661","DOI":"10.1038\/s41598-021-94250-0","article-title":"Ex vivo dendritic cell-based (DC) vaccine pulsed with a low dose of liposomal antigen and CpG-ODN improved PD-1 blockade immunotherapy","volume":"11","author":"Yazdani","year":"2021","journal-title":"Sci. Rep."},{"issue":"35","key":"10.1016\/j.jconrel.2023.01.034_bb0205","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1016\/j.vaccine.2020.06.055","article-title":"Vaccination with dendritic cells pulsed ex vivo with gp100 peptide-decorated liposomes enhances the efficacy of anti PD-1 therapy in a mouse model of melanoma","volume":"38","author":"Yazdani","year":"2020","journal-title":"Vaccine."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.034_bb0210","first-page":"297","article-title":"Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential","volume":"1","author":"Immordino","year":"2006","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0215","first-page":"93","article-title":"Utilization of thin film method for preparation of celecoxib loaded liposomes","volume":"2","author":"Moghimipour","year":"2012","journal-title":"Adv. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.jconrel.2023.01.034_bb0220","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ijpharm.2015.01.016","article-title":"Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells","volume":"479","author":"Limasale","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0225","doi-asserted-by":"crossref","DOI":"10.17795\/jjnpp-17653","article-title":"Formulation and evaluation of liposomes for transdermal delivery of celecoxib","volume":"10","author":"Moghimipour","year":"2015","journal-title":"Jundishapur J. Nat. Pharm. Prod."},{"issue":"5","key":"10.1016\/j.jconrel.2023.01.034_bb0230","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1042\/BSR20090104","article-title":"Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics","volume":"30","author":"Deniz","year":"2010","journal-title":"Biosci. Rep."},{"issue":"4","key":"10.1016\/j.jconrel.2023.01.034_bb0235","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nri1592","article-title":"Dendritic cells as therapeutic vaccines against cancer","volume":"5","author":"Banchereau","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0240","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41565-022-01089-1","article-title":"Boosting dendritic cell nanovaccines","volume":"17","author":"Mohammadzadeh","year":"2022","journal-title":"Nat. Nanotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-022-00257-2","article-title":"Research progress on dendritic cell vaccines in cancer immunotherapy","volume":"11","author":"Yu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0250","first-page":"1178874","article-title":"A novel in situ dendritic cell vaccine triggered by rose Bengal enhances adaptive antitumour immunity","volume":"2022","author":"Zhang","year":"2022","journal-title":"J Immunol Res"},{"issue":"6","key":"10.1016\/j.jconrel.2023.01.034_bb0255","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1021\/acs.accounts.9b00148","article-title":"Combining nanomedicine and immunotherapy","volume":"52","author":"Shi","year":"2019","journal-title":"Acc. Chem. Res."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0260","first-page":"303","article-title":"Expression of cyclooxygenase 2 in human malignant melanoma","volume":"61","author":"Denkert","year":"2001","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jconrel.2023.01.034_bb0265","doi-asserted-by":"crossref","first-page":"713","DOI":"10.4161\/cbt.2.6.627","article-title":"Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression","volume":"2","author":"Goulet","year":"2003","journal-title":"Cancer Biol Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.034_bb0270","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2023.01.034_bb0275","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.4049\/jimmunol.175.3.1483","article-title":"Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells","volume":"175","author":"Baratelli","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0280","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.2147\/CMAR.S178567","article-title":"Celecoxib in breast cancer prevention and therapy","volume":"10","author":"Li","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0285","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","article-title":"Tumor targeting via EPR: strategies to enhance patient responses","volume":"130","author":"Golombek","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"14","key":"10.1016\/j.jconrel.2023.01.034_bb0290","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.2174\/1389450115666140804124808","article-title":"Safety of nanoparticles in medicine","volume":"16","author":"Wolfram","year":"2015","journal-title":"Curr. Drug Targets"},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jconrel.2023.01.034_bb0300","series-title":"Nanomedicine for Ischemic Cardiomyopathy","first-page":"9","article-title":"Nanotechnology and nanomedicine","author":"Ho","year":"2020"},{"key":"10.1016\/j.jconrel.2023.01.034_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107833","article-title":"Comparison of two routes of administration of a cationic liposome formulation for a prophylactic DC vaccination in a murine melanoma model","volume":"98","author":"Yazdani","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.jconrel.2023.01.034_bb0310","article-title":"From design to clinic: engineered Nanobiomaterials for immune normalization therapy of cancer","volume":"33 (30)","author":"Saeed","year":"2021","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0315","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s12951-022-01429-2","article-title":"Application of lipid nanovesicle drug delivery system in cancer immunotherapy","volume":"20","author":"Ding","year":"2022","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0320","doi-asserted-by":"crossref","first-page":"10071","DOI":"10.1038\/s41598-017-09520-7","article-title":"Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2023.01.034_bb0325","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1038\/s41467-022-29606-9","article-title":"Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations","volume":"13","author":"Bell","year":"2022","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.jconrel.2023.01.034_bb0330","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1158\/2159-8290.CD-20-1815","article-title":"Anti-inflammatory drugs remodel the tumor immune environment to enhance immune checkpoint blockade efficacy","volume":"11","author":"Pelly","year":"2021","journal-title":"Cancer Discov."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:39:24Z","timestamp":1759163964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923000433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":66,"alternative-id":["S0168365923000433"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.034","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal celecoxib combined with dendritic cell therapy enhances antitumor efficacy in melanoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}